+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 19Years - 65Years
All Genders
Healthy Volunteers
ID07893158

Randomized Double-Blind Study of Nicotine Orodispersible Tablet Versus Placebo for Craving Relief in Adult Smokers

Led by McNeil AB · Updated on 2026-10-23

280

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating how well a nicotine orodispersible tablet Nic ODT relieves the immediate urge to smoke in adult smokers. This Phase 2, randomized, double-blind study compares Nic ODT to a placebo tablet. The goal is to understand craving relief at specific early times after taking the study drug. Participants receive either Nic ODT 2.0 mg or a placebo tablet by mouth under fasting conditions. The study measures craving relief using a visual scale at several time points within minutes after dosing. Secondary measures include safety observations up to 46 days and the time it takes for the tablet to disintegrate completely. During the study, participants are assessed through medical exams, laboratory tests, and vital sign monitoring. They complete craving assessments shortly after dosing to record changes. Safety is monitored throughout up to 46 days. Participation requires fasting and compliance with study visits and procedures, with a total involvement lasting until study completion in October 2027.

CONDITIONS

Brief Title

A Study of Nicotine Orodispersible Tablet on Craving Relief of Male and Female Smoker Volunteers

Research Team

K

Kenvue GCO Clinical Mailbox

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here